-
- Nabil Amirouchene-Angelozzi
- 1Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino, Italy.
-
- Charles Swanton
- 2University College London Cancer Institute and The Francis Crick Institute, London, United Kingdom.
-
- Alberto Bardelli
- 1Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino, Italy.
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p>Recent technological advances in the field of molecular diagnostics (including blood-based tumor genotyping) allow the measurement of clonal evolution in patients with cancer, thus adding a new dimension to precision medicine: time. The translation of this new knowledge into clinical benefit implies rethinking therapeutic strategies. In essence, it means considering as a target not only individual oncogenes but also the evolving nature of human tumors. Here, we analyze the limitations of targeted therapies and propose approaches for treatment within an evolutionary framework.</jats:p> <jats:p>Significance: Precision cancer medicine relies on the possibility to match, in daily medical practice, detailed genomic profiles of a patient's disease with a portfolio of drugs targeted against tumor-specific alterations. Clinical blockade of oncogenes is effective but only transiently; an approach to monitor clonal evolution in patients and develop therapies that also evolve over time may result in improved therapeutic control and survival outcomes. Cancer Discov; 7(8); 805–17. ©2017 AACR.</jats:p>
収録刊行物
-
- Cancer Discovery
-
Cancer Discovery 7 (8), 805-817, 2017-08-01
American Association for Cancer Research (AACR)
